Status:
WITHDRAWN
Melatonin for Delirium Prophylaxis
Lead Sponsor:
University of British Columbia
Conditions:
Delirium
Eligibility:
All Genders
65+ years
Phase:
PHASE4
Brief Summary
Delirium is a common complication of illness especially among the elderly with serious sequelae including increased mortality, morbidity and length of stay. This neuropsychiatric emergency has key fea...
Eligibility Criteria
Inclusion
- 65 years of age or greater
- Admitted to hospital under the care of the hospitalist service or sub-acute medicine wards.
Exclusion
- those who are suspected to be delirious at the time of their initial presentation;
- those who are already taking melatonin prior to admission;
- those who are not expected to live more than 48 hours;
- those suffering severe dementia (as indicated by a score of 6-7 on the Global Deterioration Scale adapted by Dr. Doug Drummond from Reisberg et al. (Reisberg 1982);
- those who are unable to reliably take oral medications;
- those presenting with an intracranial bleed, seizure or acute stroke;
- those with a known allergy or adverse reaction to the study compounds;
- those who cannot be evaluated initially because of depressed level of consciousness or inability to communicate;
- those anticipated to require surgery early in their hospitalization.
Key Trial Info
Start Date :
February 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02282241
Start Date
February 1 2016
End Date
September 1 2021
Last Update
October 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vancouver Coastal Health
Vancouver, British Columbia, Canada, V5Z 1M9